Introduction
Granulosa cell tumors comprise 3% to lO%/'of all malignant ovarian tumors. They are diagnosed at all ages, but usually occur after the menopause [11. The most common presenting symptom is abnormal uterine bleeding due to hormonal activity of the tumor. Complete surgical removal is the management of choice for these tumors. The stage at the initial operation appears to be the most important prognostic factor for cancerrelated survival. The management of metastatic disease or inoperable loco-regional relapse has yet to be defined for this uncommon ovarian tumor. The following case history illustrates a number of management problems in a patient with granulosa cell tumor of the ovary. Therapeutic options for the different stages of the disease will be discussed.
Case history
A 59-year-old woman presented with a history of abdominal discomfort and dysuria of six months' duration, with additional symptoms of dyspareunia and anal tenesmus. There was no history of vaginal discharge or bleeding. She was multiparous and had been postmenopausal for eight years. On examination the only abnormal finding was a mobile mass in her lower abdomen. Laboratory investigations including full blood count, plasma electrolytes, serum creatinine and liver function tests all showed normal results apart from an elevated lactate dehydrogenase of 369 UIL (normal ~ 250) and 17-beta-estradiol of 250 pmol/L (postmenopausal woman normal ~60). A cervical smear showed no abnormalities except for an absence of atrophy of epithelial cells. The chest X-ray picture was normal. Intravenous pyelography showed an impression on the bladder but no urethral obstruction and ultra-sound confirmed a solid mass originating in the right ovary.
An exploratory laparotomy was performed. Apart from adhesions of the enlarged right ovary to the small intestine, no abnormalities were found. Mer washout of the peritoneal cavity an infracolic omentectomy and total hysterectomy was performed with bilateral salpingo-oophorectomy including the adhesent part of the small intestine. Histological examination showed a granulosa-cell tumor of the right ovary confined within the capsule (FIGO stage IA) and a carcinoma in situ of the endometrium of the uterus. The patient's postoperative recovery was uneventful and her serum betaestradiol level returned to normal postmenopausal levels.
During follow-up the patient complained of disabling flushes which were treated successfully with conjugated estrogen 1.25 mg daily.
After two years the patient again experienced abdominal pain. On examination no tumor was found but ultra-sonography revealed an abdominal mass. Determination of her estradiol levels was not helpful due to the estrogen medication. Laparotomy was performed and in addition to extensive adhesions, two peritoneal lesions of 1.0 and 4.0 cm diameter were found. Both lesions proved to be granulosa cell tumor and could be completely resected. No adjuvant therapy was given.
Six months later a routinely performed CT scan of the abdomen showed a local recurrence and liver metastases. The endogenous 17-beta-estradiol level (after cessation of the estrogen medication) was elevated to 180 pmol/L. Palliative poly-chemotherapy was started with PVB courses; cisplatin (20 mg/m2 day 1-5), vinblastine (0.15 mglkg days 1 and 2) and bleomycin (30 mg/24-hour infusion on day 2 and 15 mg short infusion day 15) every four weeks. After two courses there was a reduction in tumor size. Mer four courses early signs of bleomycin lung toxicity were detected on the chest X-ray and bleomycin was discontinued. Mer six courses the patient developed polyneuropathy and chemotherapy was stopped. A partial response was obtained with normalization of estradiol levels and elevation of luteinizing hormone (LH), follicle-stimulating hormone (FSH) levels to postmenopausal values.
One and a half years later, four years after the initial presentation, abdominal pains recurred due to growth of the liver metastases. Elevation of her serum estradiol levels (156 pmoVL) had preceded clinical manifestations four months earlier. Chemotherapy was re-instituted with carboplatin (day 1, 340 mg adjusted to creatinine clearance of 50 mlImin) and etoposide (120 mg/m2 days 1-3) every three weeks. Again a partial response was seen after four courses, with normalization of estradiol to postmenopausal levels. No further tumor regression could be achieved and treatment was stopped after the sixth course. The response lasted only six months. A third attempt with polychemotherapy (carboplatin and etoposide) was less successful and stabilization of the tumor was the best response achieved with a total dose of six courses.
No further treatment was given and slow progression of the tumor advanced to end-stage disease one year later. At that time the patient was completely bedridden, complained of abdominal pain, loss of appetite, night-sweats and tumor-related fever. The enlarged liver extended into the pelvis and the patient became dependent on blood transfusions at lO-day intervals. Palliative therapy with dexamethasone orally 3 mg daily was started, with considerable benefit. Her subjective symptoms disappeared and the massive liver mass shrank to only a small palpable rim just below the right costal margin. The patient became transfusionindependent and was able to resume her normal daily activities. This unexpected objective response on dexamethasone lasted for one year. Fifteen months later, eight years after her initial diagnosis, the patient died of progressive disease.
Discussion points

Presenting symptoms, diagnosis and prognosis of granulosa-cell ovarian tumor
A minority of granulosa cell stromal tumors occur in children before their fifth year and may present with sexual pseudo-precocity. The majority of the tumors occur after the menopause (55%) or during reproductive life (40%) [2] . A higher incidence has been reported after ovarian stimulation with clomiphene citrate and/or gonadotrophins in patients with primary and secondary infertility [3] . Abnormal uterine bleeding due to hormonal activity of the tumor is a presenting symptom in more than one-half of the adult victims. The endometrium may show cystic hyperplasia (60%) and adenocarcinoma is reported in 3% to 13% of cases [4, 5] . Abdominal discomfort and distension is noted in one-third of the patients, of whom 8% may present with acute symptoms due to torsion or rupture of the ovarian tumor [4, 6] . Virilization is a rare complication of androgen production by the tumor. Granulosa-cell tumors are diagnosed at an early stage more often than other ovarian tumors due to their hormonal activity; they account for 70% of all feminizing ovarian tumors. Precocity in young girls, estrogenstimulated vaginal smears and cervical mucus or endometrial hyperplasia may alert the gynaecologist to the possible existence of a granulosa cell tumor. Laboratory tests may show an elevated estrogen level and low FSH and LH levels in menopausal women, but onethird of these tumors are not steroid-producing and investigations will be hampered by premenopausal status or the use of exogenous estrogens. Inhibin, a polypeptide produced by granulosa cells, is stimulated by FSH and itself inhibits the release of FSH from the pituitary gland. Elevated levels of inhibin may also act as a marker for this tumor [7] , but not specifically, as other ovarian cancers may also be associated with elevated levels of inhibin [8] . Histology is therefore necessary to prove the nature of the tumor. Thecomas must be differentiated from granulosa cell tumors and mixed granulosa-theca cell tumors. Pure thecomas are benign tumors of stromal origin, and only rarely do they recur after complete surgical removal [5] . Mixed tumors and pure granulosa-cell tumors are both malignant and have the same, less favourable prognosis. The tumors may show different histological patterns, but the pattern does not correlate with survival [9] .
Advanced clinical stage (FIGO II-IV), presence of tumor rupture, large tumor (> 5 em) and high number of mitotic figures are all associated with poor prognosis [4-6, 9, 10] . The majority of patients (78%-92%) present with FIGO stage I with five-year survival rates of 92%-98% and at 10 years of 86%-92%. The five-year survival of FIGO stage II is reported to be 57%-76%, and at 10 years 30%-61 %. Survival in FIGO stages III and IV at 5 and 10 years is 11 %-22% and 6%, respectively, but the total number of patients with advanced disease is very low in most series. The overall survival with granulosa cell tumor is more favourable than with epithelial cell cancer of the ovary. This may be at least partially due to the earlier stage at diagnosis of granulosa cell cancer, as stage for stage survivals are comparable for the two tumor types. Tumor relapses occur on an average six years after initial diagnosis, but late recurrences of more than 20 years have been reported [2] .
Initial management according to FIGO stage of granulosa-cell tumor of the ovary
The initial treatment for granulosa-cell tumor of the ovary should be a bilateral oophorectomy with hysterectomy and removal of as much metastatic disease as possible. Incomplete surgical removal is associated with a poorer overall prognosis [5, 11, 12] . There is no general consensus concerning the advisability of a conservative unilateral oophorectomy in younger patients with limited disease and a strong wish for preservation of fertility. The available retrospective studies are inconclusive. Conservative surgery was acceptable to Malkasian [2] only for patients with
